A new bioreactor system for parallel operation of microbial culture or cell culture!
The "Ambr250" is a new bioreactor system for parallel operations of microbial or cell cultures using single-use bioreactors with a capacity of 100 to 250 mL, controlled by an automated liquid handling platform. This system was developed in collaboration with two major pharmaceutical companies, based on the micro bioreactor technology held by Sartorius Stedim's TAP division. It supports the necessary culture conditions required for microbial cultivation and mammalian cell culture, which demand advanced technology, as well as applications that require larger sample collections. 【Features】 ■ Individual control of all process parameters ■ Improved operating environment ■ Efficient and rapid miniaturization system ■ Equipped for scalability to benchtop bioreactors ■ Capable of screening a wide range of culture conditions and strains or cell lines *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■ Excellent tool for process development ■ Rapid evaluation of extensive culture conditions and cell line/strain performance ■ Excellent scalability to large benchtop bioreactors ■ Reduction of infrastructure *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog(2)
Download All CatalogsNews about this product(4)
Company information
Sartorius Stedim, established in 2007 through the merger of the German company Sartorius, founded in 1870, and the French company Stedim, is a pioneer in "Single-Use Technology (SUT)." As a company capable of providing comprehensive technical support to the pharmaceutical and biotechnology industries, its cutting-edge technology is highly regarded worldwide in the fields of scientific instruments and biotechnology.